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Abstract  
  
Background: Lipoprotein-associated phospholipase A2 (Lp-PLA2) activity has been shown to 
predict calcific aortic valve stenosis (CAVS) outcomes. Our objective was to test the association 
between plasma Lp-PLA2 activity and genetically-elevated Lp-PLA2 mass/activity with CAVS in 
humans. 
 
Methods and results: Lp-PLA2 activity was measured in 890 patients undergoing cardiac 
surgery including 476 patients undergoing aortic valve replacement (AVR) for CAVS and 414 
control patients undergoing coronary artery bypass grafting. After multivariable adjustment, Lp-
PLA2 activity was positively associated with the presence of CAVS (OR=1.21 [95%CI, 1.04-
1.41] per standard deviation increment). We selected four single nucleotide polymorphisms 
(SNPs) at the PLA2G7 locus associated with either Lp-PLA2 mass or activity (rs7756935, 
rs1421368, rs1805017, and rs4498351). Genetic association studies were performed in 8 
cohorts: Quebec-CAVS (1009 cases/1017 controls), UK Biobank (1350 cases/349,043 controls), 
EPIC-Norfolk (504 cases/20,307 controls), GERA (3469 cases/51,723 controls), Malmö Diet and 
Cancer Study (682 cases/5963 controls) and 3 French cohorts (3123 cases/6532 controls) 
totalising 10,137 CAVS cases and 434,585 controls. A fixed-effect meta-analysis using the 
inverse-variance weighted method revealed that none of the four SNPs were associated with 
CAVS (OR=0.99 [95%CI, 0.96-1.02, p=0.55] for rs7756935, 0.97 [95%CI, 0.93-1.01, p=0.11] for 
rs1421368, 1.00 [95%CI, 1.00-1.01, p=0.29] for rs1805017, and 1.00 [95%CI, 0.97-1.04, p=0.87] 
for rs4498351).  
 
Conclusions: Higher Lp-PLA2 activity is significantly associated with the presence of CAVS and 
might represent a biomarker of CAVS in patients with heart disease. Results of our genetic 
association study suggest that Lp-PLA2 is however unlikely to represent a causal risk factor or 
therapeutic target for CAVS. 
 
Keywords: Lp-PLA2 activity, PLA2G7, Calcific Aortic Valve Stenosis, Coronary Artery Disease 
 
 
Key messages 
 
What is already known about this subject? Lipoprotein-associated phospholipase A2 (Lp-
PLA2) activity has been shown to predict calcific aortic valve stenosis (CAVS) outcomes.  
 
What does this study add? The results of our observational study suggest that Lp-PLA2 
activity could represent an independent biomarker for CAVS. However, we show for the first time 
that genetic variants influencing Lp-PLA2 mass or activity are not associated with CAVS in this 
large genetic association study. 
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How might this influence on clinical practice? Lp-PLA2 might represent a biomarker of 
CAVS presence. Results of our genetic association study suggest that inhibition of Lp-PLA2 
activity might not be beneficial for CAVS prevention and/or treatment. 
Introduction 
 
Calcific aortic valve stenosis (CAVS) is the most common form of heart valve disease and 
currently affects almost 3% of the population older than 65.1, 2 Replacement of the aortic valve is 
the only effective treatment for CAVS. Similar to atherosclerosis or coronary artery disease 
(CAD), the molecular mechanisms that initiate CAVS include infiltration of oxidized lipids, 
lipoproteins and inflammatory cells as well as extra-cellular matrix remodeling, degradation and 
calcification. CAD and CAVS also share similar clinical risk factors. In a large population-based 
study, we showed that risk factors associated with poor cardiovascular health (an unhealthy diet, 
physical inactivity, smoking, obesity, type 2 diabetes, hypertension and hypercholesterolemia), 
often referred to as Life’s Simple 7, are associated with CAVS incidence.3 Despite the important 
overlap between pathobiological mechanisms and clinical risk factors between CAD and CAVS, 
traditional CAD treatments have so far been ineffective in treating CAVS. Low-density lipoprotein 
(LDL) cholesterol-lowering therapies such as statins and ezetimibe had no effect in the 
prevention and treatment of CAVS in previous studies.4-6 Whether other cardiovascular drugs 
under development could be effective for the treatment of CAVS is unknown. 
 
Lipoprotein-associated phospholipase A2 (Lp-PLA2) was suggested as a driver of aortic valve 
calcification.7 In a prospective observational study of patients with mild-to-moderate CAVS, Lp-
PLA2 activity was shown to be a predictor of CAVS progression.8 An important proportion of Lp-
PLA2 in the bloodstream can be found on LDL and Lipoprotein(a) (Lp[a]) particles and both 
elevated LDL cholesterol and Lp(a) levels are potentially causal risk factors for the development 
of CAVS.9-12 However, the causality of Lp-PLA2 in the etiology of CAVS has not been 
established and whether Lp-PLA2 inhibitors such as darapladib could be used for the prevention 
and/or treatment of CAVS is unknown. On the other hand, the causality of Lp-PLA2 in 
cardiovascular disease (CVD) prevention was severely questioned following the publication of 
two large trials showing no effect of darapladib treatment on cardiovascular events and by the 
lack of association between genetic variant influencing Lp-PLA2 mass/activity on CVD.13 
 
The objective of this study was to assess the relationship between Lp-PLA2 activity and the 
presence of CAVS in patients with documented heart disease undergoing cardiac surgery. We 
also sought to determine whether the relationship between Lp-PLA2 and CAVS risk was 
potentially causal by examining genetic variants at the PLA2G7 locus associated with circulating 
Lp-PLA2 mass or activity in patients undergoing cardiac surgery as well as in the general 
population.  
 
 
Methods 
 
Laboratory analyses and study population (biomarker study) 
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Lp-PLA2 activity was measured by a commercial colorimetric activity method (Platelet-activating 
factor acetylhydrolase (PAF-AH) assay kit, Cayman Chemical, Ann Arbor, Michigan) in patients 
undergoing heart surgery at the                                                            
       (IUCPQ), Québec, Canada. Briefly, the assay uses 2-thio PAF, which serves as a 
substrate for all PAF-AHs. Upon hydrolysis of the acetyl thioester bond at the sn-2 position by 
PAF-AH, free thiols are detected using 5,5’dithio-bis-(2-nitrobenzoic acid) which absorbs 412 nm 
wavelength light. The intra- and inter-assay coefficient of variation of the assay were both below 
10%. Only patients with a tricuspid aortic valve were selected in order to study a homogeneous 
population. These patients were compared to controls scheduled for a coronary artery bypass 
grafting who had no valvular heart disease (including no aortic sclerosis) at preoperative 
echocardiography. Patients with moderate to severe aortic and/or mitral valve regurgitation 
(grade >2) were excluded. Patients with a history of rheumatic disease, endocarditis, and 
inflammatory diseases were also excluded. The study protocol was approved by the Ethics 
Committee of the IUCPQ and all patients signed a written informed consent. Patients were not 
involved in the design of the study.  
 
Study populations and single nucleotide polymorphism selection (genetic association study) 
Genetic association studies were performed in 8 cohorts: Quebec-CAVS (1009 CAVS cases and 
1017 controls), UK Biobank (1350 CAVS cases and 349,043 controls), EPIC-Norfolk (504 CAVS 
cases and 20,307 controls), GERA (3469 CAVS cases and 51,723 controls), Malmö Diet and 
Cancer Study (682 CAVS cases and 5963 controls) and 3 French cohorts (3123 CAVS cases 
and 6532 controls) totalising 10,137 CAVS cases and 434,585 controls. The cohorts are 
described in details in the Supplement. SNPs were selected based on their association with Lp-
PLA2 mass or activity levels in the study of Grallert et al.14 This meta-analysis included data 
from five community-based cohorts from the US and Europe as part of the Cohorts for Heart and 
Aging Research in Genetic Epidemiology (CHARGE) consortium, including 13,664 subjects. Lp-
PLA2 activity was assessed in the Cardiovascular Health Study (CHD), Framingham Heart 
Study (FHS) and Rotterdam Study (RS) studies using a colorimetric method (diaDexus CAM kit, 
diaDexus, Inc, San Francisco, CA, USA) or a radioactive method (Perkin Elmer Life Sciences, 
Inc, Waltham, MA, USA). Lp-PLA2 mass concentration was measured in the Atherosclerosis 
Risk in Communities (ARIC), CHD, FHS and Cooperative Health Research in the Region of 
Ausburg Study (KORA) studies using a commercial sandwich enzyme immunoassay (PLAC® 
test, diaDexus, Inc, San Francisco, CA, USA). Genotyping was performed using high-throughput 
assays and genetic imputation was performed to obtain results on >2.5 million SNPs. The SNP-
phenotype association (Lp-PLA2 mass/activity) was performed using linear regression on log-
transformed values in an additive model adjusted for age, sex and, if applicable, recruitment site. 
There was no sample overlap between the cohorts used to derive the exposure and the 
outcomes.  We selected genome-wide significant and independent SNPs (r2<0.40) at the 
PLA2G7 locus to increase the probability of true effects (Table 1). We investigated the 
association between the 4 selected SNPs (2 associated with Lp-PLA2 mass and 2 associated 
with Lp-PLA2 activity) at the PLA2G7 locus and CAVS in 8 cohorts (described in the 
supplementary data file). All study protocols were approved by local Ethics Committees and all 
patients provided informed consent. 
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Statistical analyses 
The differences between biomarkers levels in patients with versus without CAVS were tested 
using one-way analyses of variance and unpaired t-tests. The association between measured 
Lp-PLA2 activity and the presence of CAVS was determined using logistic regression and odds 
ratios (OR) for an increment of one standard deviation unit before and after adjusting for 
cardiovascular risk factors (age, sex, body mass index, diabetes, smoking, lipid-lowering therapy 
use and creatinine levels). Lp-PLA2 activity was transformed into a z score (z = (x-
mean(x))/sd(x)) to fit the logistic model. For each of the four selected SNPs, we used logistic 
regression models to verify their association with CAVS per-allele in each cohort. Models were 
adjusted for age, sex and the first 10 ancestry-based principal components when available. In 
the GERA cohort genetic variants were modelled using PLINK2 in logistic regression models 
adjusted for age, age squared, and sex. In the French cohorts, models were not adjusted for 
age. We performed a fixed-effect meta-analysis using the inverse-variance weighted method as 
implemented in the rmeta package (version 3.0) in R (version 3.3.1). Genetic study power was 
calculated using QUANTO v1.2.4 with a log-additive mode of inheritance using alleles 
frequencies provided in table 1, with the unmatched case-control ratio of our study cohorts and a 
two-tailed p-value threshold of 0.05. Statistical analyses were performed with R and SAS. 
 
 
Results 
 
Lp-PLA2 activity and calcific aortic valve stenosis 
The clinical characteristics of the study participants included in the biomarker study are 
presented in Table 2. By design, the proportion of patients with CAD was higher in controls 
compared with cases. Mean Lp-PLA2 activity was higher in patients with CAVS compared to 
controls (Figure 1).  
 
Table 3 presents the positive association between higher Lp-PLA2 activity and the presence of 
CAVS. The association between Lp-PLA2 activity and CAVS remained significant after adjusting 
for potential confounders (age, sex, body mass index, diabetes, smoking, lipid-lowering therapy 
use and creatinine levels).  
 
Genetic variants at the PLA2G7 locus, calcific aortic valve stenosis and aortic valve calcium 
The association between each SNP at the PLA2G7 locus and CAVS is presented in Figure 2. 
None of the Lp-PLA2 mass/activity raising SNPs were significantly associated with CAVS in the 
individual cohorts or in the meta-analysis. We found no evidence of heterogeneity across these 
meta-analyses (p-value for heterogeneity >0.05 for all). In addition, none of the selected SNPs 
showed a significant association with aortic valve calcification (AVC) assessed by CT and 
defined by an Agatston score >0 in 6942 participants from the CHARGE consortium: p-values 
for rs7756935, rs1421368, rs1805017 and rs4498351 were 0.15, 0.71, 0.99 and 0.052 
respectively. To determine whether SNPs included in this analysis showed pleiotropic 
associations, we used the PhenoScanner 15, 16, an online tool that provides the phenotypic 
spectrum of these SNPs. Results presented in Supplementary Table 1 suggest no association 
between these SNPs and traits (other than Lp-PLA2 mass/activity) at p-value <1,05E-5, with the 
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exception of rs1421368 associated with viral infections of unspecified site in the UK Biobank. 
 
 
Discussion 
 
Lp-PLA2 is an enzyme that hydrolyses oxidized phospholipids into lysophosphatidylcholine 
(lyso-PC), which is an important chemoattractant and pro-inflammatory mediator. Lp-PLA2 is 
secreted by inflammatory cells that is transported in the bloodstream by atherogenic lipoprotein 
particles such as LDL and Lp(a). Lp(a) is an important a likely causal risk factor for CAVS. On 
top of Lp-PLA2, Lp(a) transports oxidized phospholipids (Ox-PL) in the blood. Given the lack of a 
causal association between genetically-elevated Lp-PLA2 mass/activity and CAVS, we believe 
that Lp(a) might drive the initiation and progression of CAVS via mechanisms that are 
independent of Lp-PLA2, such as Ox-PL mediated inflammation and calcification.  
 
Prospective observational studies have shown that circulating Lp-PLA2 mass and/or activity is 
associated with CAD risk.17, 18 For instance, in a meta-analysis that included more than 79,000 
participants in 32 prospective studies, a continuous association between Lp-PLA2 activity and 
the risk of coronary heart disease was observed. In that study a relative increase in risk of 1.10 
(95% IC, 1.05 to 1.16) for each 1-SD increase in Lp-PLA2 activity was observed after adjustment 
for conventional risk factors.19 The possibility that Lp-PLA2 might be causally related to 
atherosclerosis was further supported by treatment with the Lp-PLA2 inhibitor darapladib in a 
porcine model.20 In that study, in diabetic pigs fed a hyperlipidemic diet, treatment with 
darapladib (n= 20) reduced the development of coronary atherosclerosis and inhibited the 
subsequent progression to advanced lesions, resulting in a more stable plaque phenotype 
compared to control pigs treated with placebo (n=17). A marked reduction in necrotic core 
development and a change in arterial lesion composition was observed following Lp-PLA2 
inhibition. Following these promising observations, two large-scale cardiovascular outcomes 
trials that documented the impact of the Lp-PLA2 inhibitor darapladib on health outcomes were 
launched. In both studies however, treatment of patients with stable coronary heart disease 
(STABILITY trial)21 or acute coronary syndrome (SOLID-TIMI 52 trial)22 did not lead to reductions 
in cardiovascular outcomes, which has left many to suggest that Lp-PLA2 might simply 
represent a biomarker of, rather than a causal risk factor of CAD. This observation was further 
supported by the results of Mendelian randomization studies. Mendelian randomization relies on 
the random assortment of alleles during meiosis to divide a population into groups with and 
without an elevation in a risk factor. The random distribution of inherited variants affecting the 
risk factor minimizes the possibility that reverse causation or confounding is responsible for the 
association between the risk factor and the outcome. Mendelian randomization had “predicted 
the failure” of Lp-PLA2 inhibition for ACVD risk reduction by providing evidence that variants at 
the PLA2G7 locus associated with lifelong reductions in Lp-PLA2 mass or activity were not 
associated with cardioprotection.23, 24  
 
Lp-PLA2 is involved in aortic valve mineralization. A recent transcriptomic study by Mahmut et 
al.7 revealed that the expression of Lp-PLA2 was increased more than 4-fold in calcified aortic 
valves compared to normal aortic valves in humans. In the same report, it was documented that 
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lyso-PC induced mineralization and apoptosis of the human valvular interstitial cells in vitro. A 
small study showed that Lp-PLA2 levels were higher in patients with CAVS compared to 
participants without CAVS.25 Our group also showed that higher Lp-PLA2 activity was 
associated with the progression of CAVS8 and the structural degeneration of bioprostheses.26 
 
The present study shows that elevated Lp-PLA2 activity is associated with CAVS, even when 
compared to patients with documented CAD, thereby suggesting that Lp-PLA2 activity might be 
a stronger marker of the presence of CAVS compared to CAD. However, we found no 
association between genetic variants at the PLA2G7 locus that are associated with Lp-PLA2 
mass or activity and CAVS in 8 cohorts. Consequently, Lp-PLA2 mass or activity is unlikely to 
represent a causal risk factor or therapeutic target for CAVS (Figure 3). 
 
Previous Mendelian randomization studies on CAD have used rare loss-of-function mutations 
with large effect on Lp-PLA2 activity (up to 94%) and/or common variants with modest-impact on 
the risk factor. Limitations of our study include the low absolute effects on Lp-PLA2 activity/mass 
of our selected SNPs. However, the per-allele effects of the two SNPs, rs7756935 and 
rs1421368, associated with Lp-PLA2 activity used in the genetic study correspond respectively 
to 34% and 43% of the difference of Lp-PLA2 activity observed between cases and controls in 
our biomarker study. It is also worth mentioning that the effect of these variants on Lp-PLA2 
mass or activity are lifelong effects. As CAVS is a less prevalent medical condition than ACVD, 
and mutations with large effects on Lp-PLA2 are extremely rare, we could not use genetic 
instruments with a large effect on the biomarker. To our knowledge, our present study has the 
largest number of CAVS cases collected in a genetic association study. Our sample size had 
80% power to detect per-allele odds ratios for CAVS of 1.05, 1.07, 1.05 and 1.04 respectively for 
rs7756935, rs1421368, rs1805017 and rs4498351. It must also be mentioned, however, that 
individuals included in this study were all of European ancestry. Therefore, caution is warranted 
prior to generalizing these findings to populations from other ethnic backgrounds. This limitation 
also applies to our observational study. Additional limitations of our observational study include 
the presence of a control group of patients with CAD and the fact that Lp-PLA2 activity, but not 
mass was measured. Although, the inclusion of our control of patients with CAD enabled us the 
study the association of Lp-PLA2 activity with CAVS possibly independently of the 
presence/absence of CAD, we believe that additional studies including healthy controls and 
measuring both Lp-PLA2 mass and activity would be required to confirm and extend our 
findings.  
 
The present study further consolidates the strong association between elevated Lp-PLA2 activity 
and CAVS by reporting this association in a population with a high prevalence of ACVD. 
However, the lack of association between variants influencing Lp-PLA2 mass or activity and 
CAVS suggest that, as shown for CAD, elevated Lp-PLA2 is more likely to represent a 
biomarker for CAVS rather than a causal risk factor. 
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Table 1. Single nucleotide polymorphisms included in the genetic association study.  
SNP Position Modelled allele MAF Beta (SE) 
rs7756935 6:46675025 C 0.244 0.027(0.004)* 
rs1421368 6:46696593 G 0.107 0.034(0.006)* 
rs1805017 6:46684222 T 0.255 0.043(0.004)# 
rs4498351 6:46676783 T 0.574 0.027(0.004)# 
SNP indicates single nucleotide polymorphisms, MAF indicates modelled allele frequency from 
1000 Genome European populations and SE indicates standard error. *Per allele difference in 
log Lp-PLA2 activity (nmol/min/mL). #Per allele difference in log Lp-PLA2 mass (ng/mL). 
 
Table 2. Clinical characteristics of study participants.  
 CAVS  CAD P-Value 
Number of patients 476 414  
Men 271 (57) 235 (57) 0.93 
Age, years 72.0 (8.7) 71.1 (8.7) 0.10 
Body mass index, kg/m2 28.1 (5.2) 27.5 (4.3) 0.03 
Active smokers 48 (10) 48 (12) 0.43 
Coronary artery disease 244 (51) 414 (100) <0.0001 
Diabetes 140 (29) 126 (30) 0.75 
Hypertension 339 (71) 291 (70) 0.54 
Lipid-lowering therapy 306 (64) 341 (82) <0.0001 
Total cholesterol, mmol/L 4.35 (1.07) 4.06 (0.99) <0.0001 
LDL cholesterol, mmol/L 2.41 (0.91) 2.21 (0.80) 0.0004 
HDL cholesterol, mmol/L 1.26 (0.36) 1.15 (0.34) <0.0001 
Apolipoprotein B, g/L 0.71 (0.21) 0.66 (0.20) <0.0001 
Triglycerides, mmol/L 1.51 (0.81) 1.56 (0.77) 0.30 
Creatinine, μmol/L 96.6 (40.2) 91.9 (20.1) 0.02 
Lp-PLA2, μmol/min/mL 0.017 (0.005) 0.016 (0.005) <0.0001 
Data are presented as means (SD) or N (%). CAVS indicates calcific aortic valve stenosis, CAD 
indicates coronary artery disease and Lp-PLA2 indicates lipoprotein-associated phospholipase 
A2.  
 
 
Table 3. Association between Lp-PLA2 activity and CAVS risk.  
 Per 1-SD Unit  
Unadjusted 1.33 (1.16-1.52)* 
Model 1 1.35 (1.17-1.55)* 
Model 2 1.22 (1.05-1.42)* 
Model 3 1.21 (1.04-1.41)* 
Data are presented as odds ratios (95% confidence interval). SD indicates standard deviation. 
Model 1 is adjusted for age and sex. Model 2 is adjusted for age, sex, body mass index, 
diabetes, smoking and lipid-lowering therapy use. Model 3 is adjusted for age, sex, body mass 
index, diabetes, smoking, lipid-lowering therapy use and creatinine levels. *p<0.0001. (n= 890) 
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Figure Legends 
 
Figure 1. Lp-PLA2 activity in patients with vs. without calcific aortic valve stenosis. *p=4.3x10-5 
 
Figure 2. Meta-analysis of the per-allele association between four single nucleotide 
polymorphisms associated with Lp-PLA2 mass and/or activity and CAVS risk.   
 
Figure 3. Higher Lp-PLA2 activity is significantly associated with the presence of CAVS in 
patients with heart disease, but variants influencing Lp-PLA2 mass or activity are not associated 
with CAVS in this large genetic association study.  
 
